Targeting immunogenic cell death in cancer.

Ahmed A, Tait SWG. · 2020

Read Targeting immunogenic cell death in cancer. by Ahmed A, Tait SWG. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7718954.txt.

Introduction

Ahmed and Tait review how to trigger a death in cancer cells that wakes the immune system. This death type is called immunogenic cell death. Dying cells emit danger signals that draw immune cells in. Those cells can then start a broad attack on the tumor.

The authors set out the forms this death can take and the molecules behind each. Signals include surface calreticulin, released ATP, and interferon. Some treatments already spark this death by chance. The review weighs the promise of aiming for it on purpose. It also flags the hurdles, such as tumors that suppress immune response nearby.

Catalog record

CREATORAhmed A, Tait SWG.
YEAR2020
COLLECTIONPAPERS
FORMATTXT
FILE SIZE52 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC7718954

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Targeting immunogenic cell death in cancer By Asma Ahmed, Stephen WG Tait Published in: Molecular Oncology DOI: 10.1002/1878-0261.12851 ABSTRACT Immunogenic cell death (ICD) is a form of cell death that can engage immunity. Therapeutic engagement of ICD in cancer may lead to more effective responses by eliciting antitumor immunity. Here, we discuss various modalities of ICD, highlighting our current understanding of the molecular basis of ICD. Finally, we outline the potential and challenge of harnessing ICD in cancer immunotherapy. Keywords: cancer, caspase, cell death, DAMPs, immunogenic cell death, interferon AbbreviationsATPadenosine triphosphateBAKBCL‐2 homologous antagonist killerBAXBCL‐2‐associated X proteinBCL‐2B‐cell lymphoma 2BIDBH3‐interacting domain death agonistc‐FLIPcellular FLICE‐like inhibitory proteincGAMPcyclic guanosine monophosphate–adenosine monophosphatecGAScyclic GMP‐AMP synthaseCRTcalreticulinCXCL10chemokine C‐X‐C motif ligand 10DAMPsdamage‐associated molecular patternsDCsdendritic cellsDISCdeath‐inducing signaling complexERendoplasmic reticulumFADDFAS‐associated protein with death domainFASLFAS ligandGSDMDgasdermin DGSDMDNTN‐terminal fragment of gasdermin DGSDMEgasdermin EHMGB1high‐mobility group box‐1HSPheat‐shock proteinsHyp‐PDThypericin‐based photodynamic therapyICDimmunogenic cell deathIFNinterferonIFNARIFN‐α and IFN‐β receptorsILinterleukinIRF3interferon regulatory factor 3ISGsIFN‐stimulated genesLPSlipopolysaccharideMAPKmitogen‐activated protein kinaseMHCmajor histocompatibility complexMLKLmixed‐lineage kinase‐likeMOMPmitochondrial outer membrane permeabilizationmtDNAmitochondrial DNANF‐κBnuclear factor kappa‐light‐chain‐enhancer of activated B cellsNK cellsnatural killer cellsNLRNOD‐like receptorNLRP3NOD‐like receptor family, pyrin domain‐containing 3 proteinP2RX7purinergic receptor P2X 7PD‐L1programmed death ligandPRRspattern recognition receptorsPSphosphatidyl serineRCDregulated cell deathRIPK1receptor‐interacting serine/threonine protein kinase 1RIPK3receptor‐interacting serine/threonine protein kinase 3ROSreactive oxygen speciesSTINGstimulator of interferon genestBIDtruncated form of BIDTBK1TANK‐binding kinase 1TLRToll‐like receptorTNFtumor necrosis factorTRAILTNF‐related apoptosis‐inducing ligandZBPZ‐DNA‐binding protein INTRODUCTION Immunogenic cell death (ICD) is a form of regulated cell death (RCD) that is sufficient to activate an adaptive immune response in an immunocompetent setting [1]. It has been classified as a distinct poorly defined entity induced by certain chemotherapeutic drugs, oncolytic viruses, physicochemical therapies, photodynamic therapy, and radiotherapy [1, 2]. Recently, Legrand et al. proposed to define ICD on the basis of the communication between dying and immune cells as a successful dialog between a dying cell and an appropriately disposed immune system [3]. Nevertheless, the molecular mechanisms of this interaction are yet to be defined. The long‐standing idea that the immune system functions by merely making a distinction between self and non‐self has been revised with the introduction of the danger model that posits a model in which our immune system responds to entities that cause damage as opposed to those that are simply foreign [4]. Dying or stressed cells release molecules that can function as either adjuvants or danger signals for the immune system. These signals are collectively called damage‐associated molecular patterns (DAMPs) [5]. Importantly, ICD encompasses the release of DAMPs from dying tumor cells, that are recognized by innate pattern recognition receptors (PRRs), such as Toll‐like receptors (TLRs) and NOD‐like receptors (NLRs) resulting in the activation of tumor‐specific immune responses, thus provoking long‐term efficacy of anticancer drugs by combining direct cancer cell killing and antitumor immunity, generally associated with immunological memory [1, 2]. Herein, we discuss different stimuli of ICD, the role of DAMPs in T‐cell cross‐priming, and the activation of antitumor immune response. Finally, we discuss future perspectives for therapeutic targeting of ICD in cancer therapy. IMMUNOGENICITY OF CELL DEATH PATHWAYS Accumulating evidence has shown that dying cells actively regulate immune responses as they release or expose molecules that serve as danger signals to stimulate the innate immune system. Nonetheless, the interaction between cell death trigger and the downstream molecular pathways that determines cell death immunogenicity is highly complex [3, 6]. Here, we discuss the cell death pathways commonly described to induce an immune response, focusing on apoptosis, necroptosis, and pyroptosis (Fig. 1). Other cell death modalities are extensively reviewed elsewhere [1]. [Figure: Overview of necroptosis, apoptosis, and pyroptosis signaling pathways. Binding of death ligands such as tumor necrosis factor (TNF) to their cognate receptor (TNFR) leads to pleiotropic signaling including inflammation and cell survival, apoptosis, and necroptosis, determined by the key signaling molecule, the receptor‐interacting serine/threonine protein kinase 1 (RIPK1). Upon inhibition of caspase‐8, RIPK1 activates RIPK3 leading to the formation of the necrosome. The necrosome then phosphorylates and activates mixed‐lineage kinase‐like (MLKL) that causes rapid membrane permeabilization and necroptosis. Activation of caspase‐8 leads to activation of caspase‐3 and caspase‐7 and cell death (extrinsic apoptosis). The intrinsic apoptosis pathway is initiated by perturbation in the internal environment including DNA damage that causes mitochondrial outer membrane permeabilization (MOMP). MOMP is regulated by the interaction between pro‐apoptotic and anti‐apoptotic B‐cell lymphoma 2 (BCL‐2) family proteins. The pro‐apoptotic proteins BCL‐2 associated X (BAX) and BCL‐2 homologous antagonist killer (BAK) form pores at the mitochondrial outer membrane leading to the subsequent release of cytochrome c and the formation of the APAF‐1 apoptosome. The apoptosome activates caspase‐9, which subsequently activates caspase‐3 and caspase‐7 resulting in apoptosis. Caspase‐8 mediates the crosstalk between the intrinsic and extrinsic apoptosis pathways by cleaving the pro‐apoptotic BH3‐interacting domain death (BID) to truncated BID (tBID) that activates BAX and BAK. Damage‐associated molecular patterns (DAMPs) released from dying cells activate pattern recognition receptors such as Toll‐like receptors (TLR). This leads to the activation of canonical inflammasomes that activate caspase‐1. Active caspase‐1 cleaves gasdermin D (GSDMD) liberating an N‐terminal (GSDMDNT) pore‐forming fragment from the C‐terminal (GSDMDC) inhibitory fragment. GSDMDNT form pores leading to membrane permeabilization and pyroptosis. Active caspase‐1 also cleaves the pro‐inflammatory cytokines interleukin 1β (IL‐1β) and IL‐18 into their mature form that are released by GSDMD pores.] Apoptosis 2.1. Apoptosis is a form of RCD important for development, tissue homeostasis, and immunity [7]. During apoptosis, cells undergo cytoplasmic shrinkage, nuclear fragmentation, chromatin condensation, and plasma membrane blebbing followed by the formation of apoptotic bodies that are efficiently and rapidly cleared by phagocytes [8, 9, 10]. Apoptosis is mediated by the activity of caspase proteases and can be engaged by two modes: intrinsic and extrinsic, both converge upon activation of caspase‐3 and caspase‐7 (Fig. 1) [11]. Intrinsic apoptosis is triggered by perturbation in the environment involving DNA damage, endoplasmic reticulum (ER) stress, excessive reactive oxygen species (ROS) formation, and replication stress. The key event for intrinsic apoptosis is mitochondrial outer membrane permeabilization (MOMP) [11], that is regulated by the interactions between the pro‐apoptotic and the anti‐apoptotic B‐cell lymphoma 2 (BCL‐2) family members [12]. The pro‐apoptotic proteins BCL‐2‐associated X (BAX) and BCL‐2 homologous antagonist killer (BAK) permeabilize the mitochondrial outer membrane; subsequently, cytochrome c and other soluble proteins are released from the mitochondrial intermembrane space resulting in caspase activation and cell death (Fig. 1) [11]. Extrinsic apoptosis is engaged following binding of death ligands including FAS ligand (FASL), tumor necrosis factor (TNF), or TNF‐related apoptosis‐inducing ligand (TRAIL) to their cognate receptors, FAS, TNFRSF1A, and TNFRSF10A and TNFRSF10B receptors, respectively [3]. FAS and TRAIL induce the assembly of the death‐inducing signaling complex (DISC), whereas TNF ligation induces complex I and complex II. These complexes function as a platform to regulate caspase‐8 activation [1]. The DISC is composed of FAS‐associated protein with death domain (FADD), caspase‐8, and cellular FLICE‐like inhibitory protein (c‐FLIP) [3]. In contrast to FAS and TRAIL, the primary signaling output of TNF is not death but rather cell survival via complex I that induces the activation of nuclear factor kappa‐light‐chain‐enhancer of activated B cells (NF‐κB) and mitogen‐activated protein kinase (MAPK). This ultimately leads to the production of inflammatory cytokines and prosurvival proteins such as c‐FLIP. The receptor‐interacting serine/threonine protein kinase 1 (RIPK1) is a key signaling molecule that actively determines the balance between inflammation and cell survival, apoptosis, and necroptosis, a form of caspase‐independent RCD (Fig. 1) [13]. TNF‐induced cell death is

Read the complete text